Ansell share price surges 10% as full-year revenue comes in at US$1.9b

The healthcare giant's earnings have impressed experts.

| More on:
Three excited business people cheer around a laptop in the office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Ansell share price is taking off today, gaining 9.67% to trade at $27.57
  • It comes after the company released its earnings for financial year 2022 this morning
  • Experts have seemingly responded well to its results, with one reportedly recognising "solid underlying trends"

The Ansell Limited (ASX: ANN) share price is taking off following the release of the company's full-year earnings.

The S&P/ASX 200 Index (ASX: XJO) stock has continued on an upwards trajectory after opening 1.5% higher at $25.52.

At the time of writing, the Ansell share price is $27.57, 9.67% higher than its previous close.

Let's take a closer look at today's news from the personal protection and safety solutions provider.

Ansell share price rockets 10% on earnings

As The Motley Fool Australia reported earlier, Ansell posted US$1.95 billion of revenue and US$158.7 million of operating profit for financial year 2022.

Those figures mark respective year-on-year declines of 3.7% and 35.7%, mainly due to waning demand born from COVID-19.

Its earnings per share (EPS), meanwhile, came in within guidance at US$1.252 per share. That's bolstered to US$1.386 when adjusted for costs arising from the company's exit of Russia. Its decision to abandon operations in the nation brought a 13.4 US cent impact to its EPS.

Such a result has seemingly impressed the market. It's bid the Ansell share price to a multi-week high on the back of the company's announcement. The results also appear to have pricked the ears of experts.

Macquarie's David Bailey was quoted by The Australian as saying the company's financial year 2022 earnings embody "solid underlying trends".

The publication said the company's statutory result was in line with expectations, while its adjusted earnings were ahead. The expert continued, courtesy of The Oz:

For [financial year 2023], we see commentary ex-Russia and [foreign exchange] as highlighting improved trends and a basis for growth into [financial year 2024].

Ansell posted guidance of between US$1.15 and US$1.35 of EPS for financial year 2023.

Today's gains included, the Ansell share price is 16% lower than it was at the start of 2022. It has also fallen 31% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell Ltd. and Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »